Congress trades
Genmab A/S (GMAB)
Free on iOS and Android.
About Genmab A/S
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Jan van de Winkel
- Employees
- 3,119
- Listed since
- Jun 1, 2009
- Market value
- $26.9B
- Price to earnings (12 mo)
- 31.0
- Net income per share, as reported (12 mo)
- $1.29
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 6, 2026 | $0.54 | $0.37 | $1.2B | $1.1B | EPS beatRevenue beat |
| Q1 FY2026reported May 7, 2026 | $0.09 | $0.15 | $896.0M | $905.8M | EPS missRevenue in line |
| Q4 FY2025reported Feb 17, 2026 | $0.05 | $0.46 | $1.1B | $1.1B | EPS missRevenue in line |
| Q3 FY2025reported Nov 6, 2025 | $0.65 | $0.48 | $1.0B | $1.0B | EPS beatRevenue in line |
| Q2 FY2025reported Aug 7, 2025 | $0.54 | $0.39 | $924.8M | $952.6M | EPS beatRevenue miss |
| Q1 FY2025reported May 8, 2025 | $0.31 | $0.23 | $726.0M | $755.5M | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | $360.8M | 13,133,131 | +64.8% | 2.14% |
| Orbis Allan Gray Ltd | $312.3M | 11,368,161 | -12.0% | 1.85% |
| AllianceBernstein L.P. | $231.9M | 8,644,877 | -9.5% | 1.41% |
| Deerfield Management Company, L.P. | $188.6M | 6,865,000 | +178.8% | 1.12% |
| Deep Track Capital, LP | $155.2M | 5,650,000 | +54.2% | 0.92% |
| Arrowstreet Capital, Limited Partnership | $136.7M | 4,975,324 | 0.0% | 0.81% |
| BlackRock, Inc. | $128.3M | 4,671,252 | +3.0% | 0.76% |
| Sofinnova Investments, Inc. | $111.1M | 4,045,215 | +437.7% | 0.66% |
| Renaissance Technologies LLC | $96.6M | 3,517,850 | -20.3% | 0.57% |
| Two Sigma Investments, LP | $96.3M | 3,506,843 | +49.9% | 0.57% |
| Harding Loevner LP | $86.9M | 3,086,318 | -4.5% | 0.50% |
| First Trust Advisors LP | $75.7M | 2,756,522 | +12.0% | 0.45% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding GMAB
3 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Paradigm BioCapital | $360.8M | 13,133,131 | 6.8% |
| Deerfield Management | $188.6M | 6,865,000 | 2.0% |
| Deep Track Capital | $155.2M | 5,650,000 | 2.3% |
3 of the 97 fund managers we track list GMAB shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in GMAB
11 disclosures of 11 on record · median 29d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Alan ArmstrongSelf | Stock | Purchase | $1,001 - $15,000 | +69.5%S&P 500 +20.3% · +49.3 pts vs S&P 500 | Mar 30, 2026 | Jul 21, 2026 | 113d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +106.4%S&P 500 +28.4% · +78.0 pts vs S&P 500 | Jan 16, 2025 | Feb 10, 2025 | 25d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +118.7%After the saleS&P 500 +25.2% · +93.5 pts vs S&P 500 | Dec 16, 2024 | Jan 14, 2025 | 29d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +57.8%S&P 500 +38.5% · +19.4 pts vs S&P 500 | Jul 19, 2024 | Aug 15, 2024 | 27d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +69.7%After the saleS&P 500 +38.5% · +31.2 pts vs S&P 500 | Jun 18, 2024 | Jul 9, 2024 | 21d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +34.5%S&P 500 +74.4% · -39.9 pts vs S&P 500 | Oct 16, 2023 | Nov 11, 2023 | 26d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +15.3%After the saleS&P 500 +70.9% · -55.6 pts vs S&P 500 | Sep 15, 2023 | Oct 15, 2023 | 30d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +7.1%S&P 500 +67.0% · -60.0 pts vs S&P 500 | Jul 19, 2023 | Aug 21, 2023 | 33d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +5.7%S&P 500 +68.1% · -62.5 pts vs S&P 500 | Jul 20, 2023 | Aug 21, 2023 | 32d |
| Daniel S. Goldman | Stock | Sale | $50,001 - $100,000 | +15.7%After the saleS&P 500 +72.9% · -57.3 pts vs S&P 500 | Jul 10, 2023 | Aug 13, 2023 | 34d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | +16.0%After the saleS&P 500 +85.8% · -69.8 pts vs S&P 500 | Mar 31, 2023 | Apr 17, 2023 | 17d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in GMAB, filterable by party, chamber, type and account.
Members of Congress reporting a position
1 member · estimate, as of Oct 25, 20261 member reports a position (estimated). The largest estimated position is in the $1,001 - $15,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Josh Gottheimer | Democrat · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Oct 25, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded GMAB?
Alan Armstrong, Josh Gottheimer and Daniel S. Goldman disclosed GMAB transactions in the filings shown here.
Which members of Congress hold GMAB?
1 member of Congress reports a position in GMAB in the estimate we hold as of Oct 25, 2026. The estimated position belongs to Josh Gottheimer. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are GMAB trades disclosed?
Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.